Tavaborole for the treatment of onychomycosis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1439-1448

  Elewski, Boni E ^a   Tosti, Antonella ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Nail penetration; Onychomycosis; Oxaboroles; Pharmacokinetics; Tavaborole topical solution

Indexed keywords

ANTIFUNGAL AGENT; BENZOIC ACID DERIVATIVE; CICLOPIROX; CICLOPIROXOLAMINE; FLUCONAZOLE; ITRACONAZOLE; TAVABOROLE; TERBINAFINE; AMOROLFINE; EFINACONAZOLE;

ARTICLE; BLINDNESS; CHEMICAL STRUCTURE; DERMATOPHYTE; DERMATOPHYTOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; HUMAN; IN VITRO STUDY; INFECTION RISK; MICROBIAL DIVERSITY; MOLECULAR WEIGHT; NAIL; NAIL DISEASE; OCCLUSION; ONYCHOLYSIS; ONYCHOMYCOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RADIOACTIVITY; SKIN IRRITATION; SPECTRUM; TOENAIL ONYCHOMYCOSIS; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; RISK FACTOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

NAIL PENETRATION; ONYCHOMYCOSIS; OXABOROLES; PHARMACOKINETICS; TAVABOROLE TOPICAL SOLUTION;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; HUMANS; NAILS; ONYCHOMYCOSIS; PERMEABILITY; PHARMACEUTICAL SOLUTIONS;

EID: 84902247768     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.921158     Document Type: Article

References (58)

1. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998;38(6 Pt 2):S77-86
2. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-8
3. Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010;35(5):497-519
4. Di Chiacchio N, Suarez MV, Madeira CL, Loureiro WR. An observational and descriptive study of the epidemiology of and therapeutic approach to onychomycosis in dermatology offices in Brazil. An Bras Dermatol 2013;88(Suppl 1):3-11
5. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997;36(3 Pt 1):395-402
6. Rodŕiguez-Pazos L, Pereiro-Ferreirós MM, Pereiro M Jr, Toribio J. Onychomycosis observed in children over a 20-year period. Mycoses 2011;54:450-3
7. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133:1172-3
8. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15, 000 patients. J Am Acad Dermatol 2000;43:244-8
9. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-29
10. Baran R. The nail in the elderly. Clin Dermatol 2011;29:54-60
11. Cathcart S, Cantrell W, Elewski BE. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol 2009;23:1119-22
12. Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol 1998;139:567-71
13. Zaias N. Onychomycosis. Dermatol Clin 1985;3:445-60
14. Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol 2004;140:696-701
15. Piraccini BM, Lorenzi S, Tosti A. 'Deep' white superficial onychomycosis dueto molds. J Eur Acad Dermatol Venereol 2002;16:532-3
16. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000;42(2 Pt 1):217-24
17. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-29
18. Moreno-Coutiño G, Arenas R, Reyes-Terán G. Clinical presentation of onychomycosis in hiv/aids: a review of 280 mexican cases. Indian J Dermatol 2011;56:120-1
19. de Lima AM, da Rocha SP, Reis Filho EG, et al. Study of dermatoses in kidney transplant patients. An Bras Dermatol 2013;88:361-7
20. Mayser P, Freund V, Budihardja D. Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol 2009;10:211-20
21. Lamb FM, Ottonelli Stopiglia CD, Vetoratto G, et al. Frequency of onychomycoses in chronic renal failure patients undergoing hemodialysis in Porto Alegre, Brazil. Acta Dermatovenerol Croat 2013;21:19-23
22. Fukunaga A, Washio K, Ogura K, et al. Onychomycosis as a warning sign for peripheral arterial disease. Acta Derm Venereol 2013;93:747-8
23. Abdelaziz AM, Mahmoud KM, Elsawy EM, Bakr MA. Nail changes in kidney transplant recipients. Nephrol Dial Transplant 2010;25:274-7
24. Ozkan F, Ozturk P, Ozyurt K, et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol 2013;40:107-10
25. Zaias N, Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996;35(3 Pt 2):S17-20
26. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010;28:151-9
27. Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1:19-26
28. Lamisil® (terbinafine hydrochloride) Tablets [Prescribing Information 2013]. Novartis Pharmaceuticals Corporation; East Hanover, NJ
29. Sporanox® (itraconazole) Capsules. [Prescribing Information 2012]. Janssen Pharmaceuticals, Inc; Titusville, NJ
30. Gupta AK, Konnikov N, Lynde CW, et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 1999;9:633-8
31. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Dermatol Venereol 1996;76:82-3
32. Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother 2013;57:1610-16
33. Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol 1999;141(Suppl 56):5-14
34. Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1:19-26
35. Baker SJ, Huib X, Maibach HI. Progress on new therapeutics for fungal nail infections. Ann Rep Med Chem 2005;40:323-35
36. Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci 2004;21:471-7
37. Penlac Nail Lacquer (ciclopirox) Topical Solution PI. Dermik Laboratories, A Division of Aventis Pharmaceuticals Inc; Berwyn, PA
38. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992;17(Suppl 1):44-9
39. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17(Suppl 1):41-3
40. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68:600-8
41. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139:665-71
42. Elewski BE, Rich P, Tosti A, et al. Onchomycosis: an overview. J Drugs Dermatol 2013;12:S96-103
43. Arrese JE, Pierard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003;207:255-60
44. Baker SJ, Zhang YK, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1, 3-dihydro-1-hydroxy-2, 1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006;49:4447-50
45. Barak O, Loo DS. AN-2690, a novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007;8:662-8
46. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316:1759-61
47. Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 2007;16:157-67
48. Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96:2622-31
49. Data on file. Study Report 002-NCL PK-069-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
50. Data on file. Study Report 002-NCL PP-002-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
51. Data on file. Study Report 002-NCL PP-014-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
52. Data on file. Study Report 002-CLN PK-005-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
53. Data on file. Study Report 002-CLN PK-003-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
54. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56:939-44
55. Zane LT, Pollak RA. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Presented: National American Podiatric Medical Association Annual Scientific Meeting; 16-19 August 2012; Washington, DC
56. Toledo-Bahena M, Barba-Gomez JF, Jones T, et al. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Presented: Society of Dermatology Physician Assistants; 13 November 2013; Atlanta GA
57. Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the topical treatment of toenail onychomycosis: results from two phase 3 studies. Presented: Winter Clinical Dermatology Conference; 17-22 January 2014; Kona Coast, HI
58. Data on file. Study Report 002-CLN CL-007-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA